StemCells makes controversial board appointment
This article was originally published in Clinica
Executive Summary
The California Institute of Regenerative Medicine (CIRM) has launched an internal review after Newark, California-based StemCells appointed the state stem cell agency's former president Alan Trounson to the company's board of directors. CIRM was established to oversee the distribution of grants and loans for stem cell research, which are financed by $3bn in California bond sales that were authorized by a majority of California voters who approved Proposition 71 in 2004.
You may also be interested in...
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.